Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.47 |
| ▸ | DHPS | P49366 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.40 |
| ▸ | TUBB | P07437 | 2/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1014725 | 0.78 | PARP1 (0.53) | — | |
| SCHEMBL16466013 | 0.78 | MAPK1 (0.49) | AHRHDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL1007651 | 0.76 | GPR84 (0.56) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2134129 | 0.76 | PIK3C3 (0.39) | AHRHDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL27967926 | 0.74 | TUBB4A (0.49) | AHRHDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL4522317 | 0.74 | TUBB4A (0.49) | AHRHDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL45030 | 0.74 | NR4A2 (0.63) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL30430559 | 0.74 | NR4A2 (0.63) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL7500420 | 0.72 | HDAC1 (0.48) | AHRHDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL1995385 | 0.72 | NOS1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234229-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-02-25 | — | — | US | disclosed |
| US-20230050649-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2023-02-16 | — | — | US | disclosed |
| US-11180489-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | U niversity of Virginia Patent Foundation (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3436451-B1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3782991-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | The Scripps Research Institute (US) | 2021-02-24 | — | — | EP | disclosed |
| US-20200308159-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | SPHYNKX THERAPEUTICS, LLC | 2020-10-01 | — | — | US | disclosed |
| US-10544136-B2 | Modulators of sphingosine phosphate receptors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-01-28 | — | — | US | disclosed |
| EP-2906553-B1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-26 | — | — | EP | disclosed |
| US-20190084947-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | THE SCRIPPS RESEARCH INSTITUTE | 2019-03-21 | — | — | US | disclosed |
| US-10100022-B2 | Sphingosine kinase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-10-16 | — | — | US | disclosed |
| US-7678820-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2010-03-16 | — | — | US | disclosed |
| US-7678820-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2010-03-16 | — | — | US | disclosed |
| US-20100010001-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-01-14 | — | — | US | disclosed |
| CN-101611033-A | Indole derivatives as S1P1 receptor agonists | GLAXO GROUP LTD (GB) | 2009-12-23 | — | — | CN | disclosed |
| EP-2091949-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009080663-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090076070-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090076070-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-2003132-A1 | HETERO COMPOUND | Astellas Pharma Inc. (JP) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008074821-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234229-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | SPHK1, SPHK2, S1PR2 | AHR 2763/4885HDAC1 1189/4885HDAC2 650/4885 |
| US-10544136-B2 | Modulators of sphingosine phosphate receptors | S1PR1, S1PR3, S1PR2 | AHR 2411/4885HDAC1 2260/4885HDAC2 2825/4885 |
| US-20190084947-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | S1PR1, S1PR3, S1PR2 | AHR 3116/4885HDAC1 2635/4885HDAC2 3048/4885 |
| US-20200308159-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | SPHK1, SPHK2, S1PR2 | AHR 2763/4885HDAC1 1189/4885HDAC2 650/4885 |
| US-10100022-B2 | Sphingosine kinase inhibitors | SPHK1, SPHK2, S1PR2 | AHR 2636/4885HDAC1 1387/4885HDAC2 753/4885 |
| US-20230050649-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | SPHK1, SPHK2, S1PR2 | AHR 2763/4885HDAC1 1189/4885HDAC2 650/4885 |
| US-20090076070-A1 | HETERO COMPOUND | S1PR1, ENPP2, LPAR1 | AHR 829/4885HDAC1 2035/4885HDAC2 2816/4885 |
| US-11180489-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | SPHK1, SPHK2, S1PR2 | AHR 2763/4885HDAC1 1189/4885HDAC2 650/4885 |
| US-20100010001-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | S1PR1, S1PR3, S1PR4 | AHR 3213/4885HDAC1 2580/4885HDAC2 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.